SCHEMBL5937201

SCHEMBL5937201

O=C(O)c1ccc(-c2ccc(NC(=O)C(F)(F)F)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC7 Q8WUI4 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ CA12 O43570 1/20 0.51
▸ CA1 P00915 1/20 0.51
▸ CA2 P00918 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ EPHX2 P34913 3/20 0.51
▸ FAAH O00519 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.50
▸ BCL2L1 Q07817 1/20 0.50
▸ BAD Q92934 1/20 0.50
▸ MITF O75030 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434636 0.94 CA12 (0.56) RAB9AKMT2AMEN1NPC1TP53
SCHEMBL8755361 0.85 RAB9A (0.71) RAB9AKMT2AMEN1NPC1TP53
SCHEMBL3765919 0.79 CA12 (0.59) RAB9AKMT2AMEN1NPC1TP53
SCHEMBL19227678 0.79 CA12 (0.51) RAB9AKMT2AMEN1NPC1TP53
SCHEMBL13210658 0.78 MEN1 (0.51) RAB9AKMT2AMEN1NPC1TP53
SCHEMBL25845706 0.78 CA12 (0.59) RAB9AKMT2AMEN1NPC1TP53
SCHEMBL7428282 0.78 MAPT (0.60) RAB9AKMT2AMEN1NPC1HDAC1
SCHEMBL7428266 0.78 CA12 (0.54) RAB9AKMT2AMEN1NPC1TP53
SCHEMBL16592197 0.77 PTPN1 (0.75) RAB9AKMT2AMEN1NPC1ALDH1A1
SCHEMBL24513853 0.77 LNPEP (0.50) RAB9AKMT2AMEN1HDAC8CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060052384-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia GLAXO GROUP LIMITED (GB) 2006-03-09 — — US disclosed
EP-1539158-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2005-06-15 — — EP disclosed
WO-2004006922-A1 ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA GLAXO GROUP LIMITED (GB) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052384-A1 Aryl piperidine derivatives as inducers of ldl-receptor expression for the treatment of hypercholesterolemia LDLR, NR1H2, NR1H3 RAB9A 2667/4885KMT2A 695/4885MEN1 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback